Overview

Using bioinformatics, VBI analyzes thousands of viral sequences isolated from infected individuals worldwide to let nature indicate regions of the virus that are most vulnerable to immune-based therapies. Using its proprietary Variosite technology, VBI produces synthetic vaccines that represent the diversity of viral sequences in these variable regions, an approach that differs from all past and current vaccine strategies.

VBI has leveraged its expertise in multi-strain, multi-subtype viruses with the design of a broadly reactive influenza vaccine and an avian influenza vaccine. These influenza vaccines are designed to protect against many strains or variants of influenza, and produce a broadly reactive immune response. VBI’s Influenza Vaccines can eliminate significant business and regulatory risks associated with the current practice of producing a new vaccine formulation each year. Its synthetic production and broadly reactive design provides broad and strong immunologic protection and is able to overcome many of the hurdles associated with traditional egg-based and recent cell-culture based vaccines.

VBI’s second product is a therapeutic HIV vaccine (VLP-0012M) that induces a broad immune response against many genetically distinct subtypes of HIV and empowers the immune system to control HIV infection. Given the geographic distribution of HIV subtypes, the vaccine holds tremendous promise as a global solution to the threat of HIV.

Variosite™ Technology: Advantages of the Synthetic Approach

Variations’ proprietary Variosite™ technology allows for the design and synthesis of synthetic immunogens that account for the genetic variability of HIV, influenza, or other “mutating” viruses. The synthetic process greatly reduces the risk of toxicity as no live biologics are required. This provides a significant regulatory, cost and time advantage.

Variation’s manufacturing process has been validated by a third party GMP/GLP manufacturer. It is anticipated that the company’s manufacturing process will reduce production time for new vaccines, from the typical 28-30 weeks using egg or cell culture methods down to 6 weeks, allowing for a faster and more cost efficient response to emerging strains of influenza or other viruses.